ABSTRACT
As the current COVID-19 pandemic progresses, more symptoms and signals related to how the disease manifests in the human body arise in the literature. Skin lesions and coagulopathies may be confounding factors on routine care and patient management. We analyzed the metabolic and lipidic profile of the skin from COVID-19 patients using imprints in silica plates as a non-invasive alternative, in order to better understand the biochemical disturbances caused by SARS-CoV-2 in the skin. One hundred and one patients (64 COVID-19 positive patients and 37 control patients) were enrolled in this cross-sectional study from April 2020 to June 2020 during the first wave of COVID-19 in São Paulo, Brazil. Fourteen biomarkers were identified related to COVID-19 infection (7 increased and 7 decreased in COVID-19 patients). Remarkably, oleamide has shown promising performance, providing 79.0% of sensitivity on a receiver operating characteristic curve model. Species related to coagulation and immune system maintenance such as phosphatidylserines were decreased in COVID-19 patients; on the other hand, cytokine storm and immunomodulation may be affected by molecules increased in the COVID-19 group, particularly primary fatty acid amides and N-acylethanolamines, which are part of the endocannabinoid system. Our results show that skin imprints may be a useful, noninvasive strategy for COVID-19 screening, by electing a pool of biomarkers with diagnostic potential.
- Mass spectrometry
- COVID-19
- skin imprint
- metabolomics
- SARS-CoV-2
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors would like to thank the network involved in sample collection, clinical data curation and diagnosis, in special to Paulínia Municipal Hospital and Sumaré State Hospital (CAAE 31049320.7.1001.5404) for providing samples to the initial steps of method development, and Thermo Scientific and LADETEC (UFRJ) for the technology support. This work was supported by São Paulo Research Foundation (FAPESP) [2019/05718-3 to JD, 2018/10052-1 to WJF, 2020/04705-2 to JCN and TFD], and Coordination for the Improvement of Higher Education Personnel (CAPES) [88887.513974/2020-00 to ANO].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients were recruited at Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP) localized in São Paulo city in Brazil from April to June 2020. The study was conducted according to principles expressed in the Declaration of Helsinki. Ethical approval was given by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP ethics committee (CAAE 32077020.6.0000.0005), and a signed consent form was collected from participants before enrolment.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Biomarkers elucidation data through mass spectrometry is available as supporting information Pre-processed mass spectrometry data will be available at Zenodo following publication. De-identified patient information will be made available from corresponding author upon request.
